This morning, DOR BioPharma informed the Securities and Exchange Commission it has allowed a potential acquisition to lapse. The Miami-based biotechnology firm had signed a letter of intent to buy Copenhagen, Denmark-based Gastrotech Pharma A/S in the latter part of last year. However, DOR (AMEX: DOR - News) has told the SEC it did not renew the letter of intent to buy the hormone therapeutics firm. That letter, DOR said, expired Jan. 15.
